Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.2878
Abstract: Importance There is an increasing body of literature that supports the use of rituximab as a first-line steroid-sparing agent in pemphigus vulgaris. However, the cost of rituximab is substantial compared with conventional agents, and there… read more here.
Keywords: rituximab biosimilars; cost; pemphigus vulgaris; mycophenolate mofetil ... See more keywords
Safety of switching between rituximab biosimilars in onco-hematology
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-85563-1
Abstract: Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between different… read more here.
Keywords: hematology; safety; safety switching; rituximab biosimilars ... See more keywords